Boehringer Ingelheim

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.
NC

Niklas Czeloth

Investment Manager

Kanad Das

Investment Director

Alexander Ehlgen

Investment Manager

Knut Elbers

Director and Investment Manager

Frank Kalkbrenner

Global Head

Sebastian Kreuz

Executive Director

Debbie Lin

Executive Director

DM

Detlev Mennerich

Investment Manager

PM

Philipp Müller

Executive Director

SP

Stefan Pflanz

Executive Director

Mark Ralph

Executive Director

Oliver Reuss

Executive Director

Fei Shen

Investment Director

Ilka Wicke

Director and Investment Manager

JZ

Johannes Zanzinger

Investment Manager

WZ

Weiyi Zhang

MD

93 past transactions

Rigontec GmbH

Series A in 2015
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

Vira Therapeutics

Series A in 2015
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology.

Actym Therapeutics, Inc.

Series A in 2020
Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor. It was founded in 2017 and headquartered in San Francisco, California.

NBE-Therapeutics

Series B in 2018
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Sentien Biotechnologies, Inc. develops proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions, a combinational mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repairing response. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

Greybox Solutions

Series A in 2018
Greybox Solution is a digital turbo-charged healthcare platform.

AgomAb Therapeutics N.V.

Series A in 2019
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Okairos

Series B in 2010
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

AgomAb Therapeutics N.V.

Series B in 2021
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Amal Therapeutics

Acquisition in 2019
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

OncoMyx Therapeutics

Series A in 2019
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit of cancer patients.

Global Stem cell Technology

Acquisition in 2020
Global Stem cell Technology is a veterinary biotech company to develop and produce state-of-the art stem cell products for horses and dogs.

Eyevensys

Venture Round in 2013
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.

T3 Pharmaceuticals

Series C in 2020
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.

DiogenX

Series A in 2023
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

Northern Biologics Inc.

Acquisition in 2020
Northern Biologics use state-of-the-art antibody discovery to tackle novel and challenging targets in oncology and fibrosis. Its therapeutic antibody candidates are derived from a state-of-the-art phage display platform developed and refined by world-leading researchers at the University of Toronto, and we focus on developing novel functional modulators of key signaling pathways in cancer and fibrosis. Northern Biologics was founded in 2014 and headquartered in Toronto, Ontario, Canada.

Optina Diagnostics

Series A in 2021
Optina Diagnostics Inc. develops a technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Its Optina Diagnostic retinal imaging test serves the healthcare industry. The company was founded in 2010 and is headquartered in Montréal, Canada.

Nuevocor

Series A in 2021
Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.

Rgenta Therapeutics, Inc.

Seed Round in 2020
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Rigontec GmbH

Series A in 2016
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

DiogenX

Seed Round in 2020
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

Vira Therapeutics

Acquisition in 2018
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Topas Therapeutics GmbH

Series A in 2017
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Ruipeng Pet Medical Group

Venture Round in 2020
Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services.

ImCheck Therapeutics SAS

Series A in 2017
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

eTheRNA immunotherapies

Series B in 2020
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Wellth

Series A in 2020
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.

NBE-Therapeutics

Series A in 2015
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Brainomix Limited

Series B in 2021
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.

AgomAb Therapeutics N.V.

Series A in 2019
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

OncoMyx Therapeutics

Series B in 2021
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit of cancer patients.

AbeXXa Biologics Inc.

Acquisition in 2021
Abexxa Biologics is a biopharmaceutical company that focuses on discovering and developing breakthrough antibody-based drugs designed to revolutionize cancer treatments by providing highly effective targeted therapies. Its mission is to develop products that revolutionize the treatment of cancer through activation of the immune cells to destroy the tumor. The company was founded in 2015 and is headquartered in Arlington, Texas.

OncoMyx Therapeutics

Series B in 2021
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit of cancer patients.

Topas Therapeutics GmbH

Series B in 2021
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Dopavision

Series A in 2021
Dopavision GmbH develops a digital drug that treats myopia by targeting the neurotransmitter cascade and regulates the size of the eyeball. The company was founded in 2017 and is based in Berlin, Germany.

NBE-Therapeutics

Series B in 2016
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Sentieon, Inc.

Series A in 2017
Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include Sentieon DNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation. The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California.

Aelin Therapeutics NV

Series A in 2017
Aelin Therapeutics NV develops antibiotics and therapeutics using the Pept-in technology. The company's technology platform harnesses protein aggregation to induce functional knockdown of a target protein. The company's products have applications against Methicillin-resistant Staphylococcus aureus (MRSA) and undruggable targets in humans. The company was founded in 2017 and is headquartered in Heverlee, Belgium.

Abalos Therapeutics

Series A in 2021
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.

xCures

Series A in 2021
The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, with an AI-based precision oncology platform that tightly integrates cancer research and care. The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives.

Bodyport Inc.

Series A in 2020
Bodyport Inc. manufactures sensor fitted weighing scales for cardiac patients. It offers Bodyport, a biomarker-driven virtual clinic for the prevention and management of heart disease. Its device measures blood pressure, heart rate, heart rate variability, arterial stiffness, and health assessment through a person’s feet. The company also provides online patient portal and educational materials. The company was incorporated in 2015 and is based in San Francisco, California.

Wellth

Seed Round in 2018
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.

Dopavision

Seed Round in 2019
Dopavision GmbH develops a digital drug that treats myopia by targeting the neurotransmitter cascade and regulates the size of the eyeball. The company was founded in 2017 and is based in Berlin, Germany.

Amal Therapeutics

Series B in 2018
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Rinri Therapeutics

Seed Round in 2019
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.

MabVax Therapeutics

Post in 2018
MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

ImCheck Therapeutics SAS

Series B in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

HepaRegeniX

Series B in 2020
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a key regulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.

Rinri Therapeutics

Venture Round in 2021
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.

Actimis Pharmaceuticals

Acquisition in 2008
Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.

T3 Pharmaceuticals

Series B in 2019
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.

HepaRegeniX

Series A in 2016
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a key regulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.

T-knife

Seed Round in 2018
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

HOOKIPA Pharma Inc.

Series B in 2016
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Metabomed

Series B in 2019
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

HOOKIPA Pharma Inc.

Series B in 2013
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

T-knife

Series A in 2020
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

AIgnostics

Seed Round in 2020
Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of precise heatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis. The company was founded in 2018 and is headquartered in Berlin, Germany.

Metabomed

Series A in 2016
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Rigontec GmbH

Series A in 2014
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

HOOKIPA Pharma Inc.

Series C in 2017
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Brainomix Limited

Venture Round in 2018
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.

Acousia Therapeutics GmbH

Series A in 2016
Acousia Therapeutics GmbH is a biotech company that specializes in identifying small molecules for the treatment of hearing loss. It develops drugs for local application, which protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons, such as noise trauma, treatment with ototoxic drugs, or sudden deafness. The company was founded in 2012 and is based in Tubingen, Germany.

ArmaGen Technologies

Series A in 2012
ArmaGen, Inc. is a clinical stage biotechnology company that develops therapies to treat severe neurological diseases. The company focuses on therapies for lysosomal storage, hunter syndrome, hurler syndrome, Sanfilippo A syndrome, metachromatic leukodystrophy, and neurodegenerative diseases. Its product candidates include AGT-182 for hunter syndrome; and AGT-181 for hurler syndrome. The company was formerly known as ArmaGen Technologies, Inc. ArmaGen, Inc. was incorporated in 2001 and is headquartered in San Diego, California.

NBE-Therapeutics

Series C in 2020
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

ICD Therapeutics

Acquisition in 2019
ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.

STAT-Dx

Series C in 2016
STAT-Dx Life S.L. develops, manufactures, and markets molecular diagnostic systems. The company offers a DiagCORE Cartridge for syndrome testing; DiagCORE Analyzer for modular syndrome testing analysis; DiagCORE Respiratory Panel for identification of signs and symptoms of viral and bacterial pathogens; and DiagCORE Gastrointestinal Panel for information on pathogens causing gastrointestinal infections. It also offers central nervous system panel, pneumonia panel, and blood culture identification panels. STAT-Dx Life S.L. was formerly known as STAT-Diagnostica & Innovation, S.L. The company was founded in 2010 and is based in Barcelona, Spain. As of April 27, 2018, STAT-Dx Life S.L. operates as a subsidiary of QIAGEN N.V.

Libra Therapeutics

Series A in 2020
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

Topas Therapeutics GmbH

Series B in 2020
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

eTheRNA immunotherapies

Series A in 2016
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Amal Therapeutics

Series A in 2016
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Perfood

Series A in 2020
Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects.

Acousia Therapeutics GmbH

Series B in 2018
Acousia Therapeutics GmbH is a biotech company that specializes in identifying small molecules for the treatment of hearing loss. It develops drugs for local application, which protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons, such as noise trauma, treatment with ototoxic drugs, or sudden deafness. The company was founded in 2012 and is based in Tubingen, Germany.

NBE-Therapeutics

Seed Round in 2013
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Labor Dr. Merk & Kollegen

Acquisition in 2020
LABOR DR. MERK & KOLLEGEN GMBH was founded in 1971 with the goal of developing and producing high quality diagnostics for medical use. Over the years, they gained extensive knowledge in biotechnology, virology, microbiology and toxicology and provide this know-how to external parties. They hold excellent expertise in biosafety testing of products from pharmaceutical industries or medical device manufacturers. Especially in the fields of virological and microbiological testing a wide range of GMP and GLP compliant methods for preclinical studies or quality control of final products are available. Our highly qualified and experienced team will provide personal consultation during study design and test performance, and they guarantee an economical and reliable solution to our customers’ needs.

NBE-Therapeutics

Acquisition in 2020
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Abalos Therapeutics

Series A in 2019
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.

Amal Therapeutics

Series B in 2017
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Eyevensys

Series B in 2020
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.

STAT-Dx

Series B in 2013
STAT-Dx Life S.L. develops, manufactures, and markets molecular diagnostic systems. The company offers a DiagCORE Cartridge for syndrome testing; DiagCORE Analyzer for modular syndrome testing analysis; DiagCORE Respiratory Panel for identification of signs and symptoms of viral and bacterial pathogens; and DiagCORE Gastrointestinal Panel for information on pathogens causing gastrointestinal infections. It also offers central nervous system panel, pneumonia panel, and blood culture identification panels. STAT-Dx Life S.L. was formerly known as STAT-Diagnostica & Innovation, S.L. The company was founded in 2010 and is based in Barcelona, Spain. As of April 27, 2018, STAT-Dx Life S.L. operates as a subsidiary of QIAGEN N.V.

Cardior Pharmaceuticals

Series A in 2017
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.

Tacalyx

Seed Round in 2019
Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.

Funxional Therapeutics

Acquisition in 2012
Funxional Therapeutics Ltd. develops pharmaceutical products in the United Kingdom. Its product candidates include BN83470 for the treatment of respiratory indications, initially asthma; BN83250 for the prevention of surgical adhesion formation and for the treatment of stroke; and FX125L, an orally available small molecule that belongs to a therapeutic class named broad spectrum chemokine inhibitors. The company also offers early stage preclinical programs that focus on Alzheimer's disease, autoimmune disorders, and pain and diabetes. Funxional Therapeutics Ltd. as founded in 2005 and is based in Cambridge, the United Kingdom.

Click Therapeutics

Funding Round in 2020
Click Therapeutics, Inc. engineers, validates, develops, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. It develops and commercializes novel digital therapeutics for various indications, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Click Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

Rewind Therapeutics

Series A in 2018
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

International Diagnostic Technology

Acquisition in 1978
International Diagnostic Technology is a manufacturer of diagnostic kits for food safety, and for drugs of abuse in dogs and horses. It was established in St. Joseph, Michigan.